Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration ...
(RTTNews) - MiNK Therapeutics (INKT), a clinical-stage company, said new translational data supporting the role of invariant natural killer T or iNKT cells in idiopathic pulmonary fibrosis or IPF were ...
SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...
Hypothyroidism is a significant risk factor for IPF, with a higher prevalence in IPF patients compared to the general population. Mendelian randomization confirmed the association between ...